Attovia Therapeutics ATTO
$15.10 −$0.48 (-3.08%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $15.10 0.00%
Open$15.40
Prev close$15.58
Day range$14.80 – $15.46
Volume372.2K
Market cap$690.26M
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00-100.0% YoY
Operating profit-$25.02M-60.4% YoY
Net profit-$22.27M-61.6% YoY
Diluted EPS-$0.76-41.6% YoY
Free cash flow-$25.69M-65.4% YoY
Operating cash flow-$25.67M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Operating margin-5,945.5%
Net margin-5,477.2%
Return on equity-19.8%
Return on assets-19.2%
Return on invested capital-21.3%
Current ratio34.66
Liabilities / assets3.4%
Cash & investments$395.94M
Total debt$1.74M
Net cash (debt)$394.20M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $0.00 | $450,000.00 | – | $1.35M | $990,000.00 |
| Total Operating Revenue | $0.00 | $450,000.00 | $0.00 | $1.35M | $990,000.00 |
| Operating Expense | $25.02M | $22.25M | $19.96M | $68.51M | $19.82M |
| Selling and Admin Expenses | $4.73M | $3.31M | $3.21M | $14.36M | $3.43M |
| -General & Admin Expense | $4.73M | $3.31M | $3.21M | $14.36M | $3.43M |
| Research & Development | $20.29M | $18.95M | $16.75M | $54.15M | $16.39M |
| Operating Profit | -$25.02M | -$21.80M | -$19.96M | -$67.16M | -$18.83M |
| Net Non-Operating Interest Income (Expense) | $2.79M | $1.14M | $1.33M | $6.63M | $1.61M |
| Non-Operating Interest Income | $2.79M | $1.14M | $1.33M | $6.63M | $1.61M |
| Other Income (Expense) | -$34,000.00 | -$25,000.00 | -$27,000.00 | -$95,000.00 | -$30,000.00 |
| Other Non-Operating Income (Expenses) | -$34,000.00 | -$25,000.00 | -$27,000.00 | -$95,000.00 | -$30,000.00 |
| Pretax Profit | -$22.27M | -$20.69M | -$18.66M | -$60.63M | -$17.26M |
| Net Profit | -$22.27M | -$20.69M | -$18.66M | -$60.63M | -$17.26M |
| Profit from Continuing Operations | -$22.27M | -$20.69M | -$18.66M | -$60.63M | -$17.26M |
| Net Income to Parent Company | -$22.27M | -$20.69M | -$18.66M | -$60.63M | -$17.26M |
| Other Preferred Stock Dividends | $0.00 | $0.00 | $0.00 | $271,000.00 | $0.00 |
| Net Income to Common Stockholders | -$22.27M | -$20.69M | -$18.66M | -$60.90M | -$17.26M |
| Basic EPS | -$0.76 | -$0.48 | -$0.73 | -$2.37 | -$0.67 |
| Diluted EPS | -$0.76 | -$0.48 | -$0.73 | -$2.37 | -$0.67 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $411.82M | $128.35M | $146.09M | $165.89M | $165.89M |
| Total Current Assets | $404.52M | $118.40M | $136.64M | $156.30M | $156.30M |
| Cash and Cash Equivalents & Short-Term Investments | $395.94M | $115.13M | $132.62M | $152.27M | $152.27M |
| -Cash and Cash Equivalents | $115.37M | $32.83M | $43.30M | $40.19M | $40.19M |
| -Short Term Investments | $280.57M | $82.30M | $89.33M | $112.08M | $112.08M |
| Other Current Assets | $8.58M | $3.27M | $4.02M | $4.03M | $4.03M |
| Total Non-Current Assets | $7.31M | $9.95M | $9.44M | $9.60M | $9.60M |
| Net PPE | $6.32M | $6.92M | $7.49M | $7.87M | $7.87M |
| -Gross PPE | $8.15M | $8.51M | $8.83M | $8.96M | $8.96M |
| -Accumulated Depreciation | -$1.83M | -$1.59M | -$1.34M | -$1.10M | -$1.10M |
| Other Non-Current Assets | $990,000.00 | $3.03M | $1.95M | $1.73M | $1.73M |
| Total Liabilities | $14.08M | $273.81M | $271.60M | $273.33M | $273.33M |
| Total Current Liabilities | $11.67M | $12.62M | $9.80M | $11.01M | $11.01M |
| Payables | $4.23M | $6.00M | $2.56M | $3.55M | $3.55M |
| -Accounts Payable | $4.23M | $6.00M | $2.56M | $3.55M | $3.55M |
| Current Accrued Expenses | $2.45M | $2.67M | $3.52M | $1.98M | $1.98M |
| Short-Term Debt and Capital Lease Obligation | $2.10M | $2.04M | $1.98M | $1.92M | $1.92M |
| -Current Capital Lease Obligation | $2.10M | $2.04M | $1.98M | $1.92M | $1.92M |
| Current Deferred Liabilities | $0.00 | $0.00 | $450,000.00 | $450,000.00 | $450,000.00 |
| Total Non-Current Liabilities | $2.41M | $261.19M | $261.80M | $262.32M | $262.32M |
| Long Term Debt and Capital Lease Obligation | $1.74M | $2.29M | $2.83M | $3.34M | $3.34M |
| -Long Term Capital Lease Obligation | $1.74M | $2.29M | $2.83M | $3.34M | $3.34M |
| Convertible preferred securities | $0.00 | $258.23M | $258.23M | $258.23M | $258.23M |
| Other Non-Current Liabilities | $672,000.00 | $678,000.00 | $750,000.00 | $755,000.00 | $755,000.00 |
| Total Equity | $397.74M | -$145.46M | -$125.52M | -$107.44M | -$107.44M |
| Stockholders' Equity | $397.74M | -$145.46M | -$125.52M | -$107.44M | -$107.44M |
| Capital Stock | $5,000.00 | $1,000.00 | $1,000.00 | $1,000.00 | $1,000.00 |
| -Common Stock | $5,000.00 | $1,000.00 | $1,000.00 | $1,000.00 | $1,000.00 |
| Additional Paid-In Capital | $570.91M | $4.97M | $4.18M | $3.47M | $3.47M |
| Retained Earnings | -$172.62M | -$150.35M | -$129.67M | -$111.01M | -$111.01M |
| Gains/Losses Not Affecting Retained Earnings | -$548,000.00 | -$79,000.00 | -$27,000.00 | $99,000.00 | $99,000.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$25.67M | -$16.79M | -$18.14M | -$59.20M | -$17.34M |
| Net cash flow from continuing operations | -$25.67M | -$16.79M | -$18.14M | -$59.20M | -$17.34M |
| Net Income from Continuing Operations | -$22.27M | -$20.69M | -$18.66M | -$60.63M | -$17.26M |
| Depreciation & Depletion & Amortization | $248,000.00 | $246,000.00 | $242,000.00 | $804,000.00 | $231,000.00 |
| Other Non-Cash Items | $411,000.00 | $402,000.00 | $393,000.00 | $48,000.00 | -$605,000.00 |
| Change in Working Capital | -$5.50M | $2.64M | -$541,000.00 | $276,000.00 | $105,000.00 |
| -Change in Prepaid Assets | -$4.12M | $850,000.00 | $122,000.00 | -$420,000.00 | -$932,000.00 |
| -Change in Payables and Accrued Expense | -$373,000.00 | $2.25M | -$216,000.00 | $1.30M | $1.20M |
| -Change in Other Current Assets | -$511,000.00 | $14,000.00 | $11,000.00 | -$98,000.00 | $11,000.00 |
| -Change in Other Current Liabilities | -$488,000.00 | -$478,000.00 | -$458,000.00 | -$509,000.00 | -$169,000.00 |
| Net cash flow from investing | -$199.75M | $6.88M | $22.49M | -$73.46M | $7.74M |
| Net Cash Flow from Continuing Investing Activities | -$199.75M | $6.88M | $22.49M | -$73.46M | $7.74M |
| Net PPE Purchase and Sale | -$17,000.00 | -$73,000.00 | -$288,000.00 | -$2.31M | -$52,000.00 |
| Net Investment Purchase and Sale | -$199.73M | $6.95M | $22.77M | -$71.14M | $7.79M |
| Financing Cash Flow | $307.96M | -$556,000.00 | -$1.24M | $142.01M | $33,000.00 |
| Net Cash Flow from Continuing Financing Activities | $307.96M | -$556,000.00 | -$1.24M | $142.01M | $33,000.00 |
| Net Common Stock Issuance | $309.37M | $31,000.00 | $11,000.00 | $194,000.00 | $34,000.00 |
| Net Preferred Stock Issuance | $0.00 | $0.00 | $0.00 | $142.19M | $0.00 |
| Net Other Financing Charges | -$1.41M | -$587,000.00 | -$1.25M | -$376,000.00 | -$1,000.00 |
| Ending Cash Balance | $115.77M | $33.23M | $43.70M | $40.60M | $40.60M |
| Net Change in Cash | $82.54M | -$10.47M | $3.10M | $9.36M | -$9.57M |
| Beginning Cash Balance | $33.23M | $43.70M | $40.60M | $31.24M | $50.17M |
| Free Cash Flow | -$25.69M | -$16.86M | -$18.43M | -$61.51M | -$17.40M |
| Gain/Loss from Continuing Operations | – | – | – | $7,000.00 | $0.00 |
| Net Issuance Payments Of Debt | – | – | – | $0.00 | – |
No comments yet — be the first to weigh in on ATTO.
Sign in to join the discussion.